Evonik Industries (EVK) Q4 2024 earnings summary

Executive summary

• Achieved 25% EBITDA growth in 2024, meeting or exceeding targets, with strong free cash flow and a stable dividend, supported by broad-based divisional performance and a strategic reorganization.

• Annual financial statements for 2024 audited with an unqualified opinion, confirming compliance with German commercial law and a true and fair view of assets, liabilities, and financial performance.

• Confident in delivering further earnings growth in 2025, supported by cost savings, innovation, and favorable market dynamics.

Financial highlights

• FY 2024 sales at €15,157m, down 1% year-over-year; adjusted EBITDA rose to €2,065m (+25%).

• Free cash flow for FY 2024 at €873m (42% cash conversion rate); net financial debt reduced to €3,253m.

• Dividend of €1.17 per share proposed, totaling €545.2 million, fully covered by FCF.

• Net income after taxes increased to €781 million (2023: €651 million).

• Q4 results impacted by seasonality and one-time effects; underlying business performance remains strong.

Outlook and guidance

• FY 2025 adjusted EBITDA guidance: €2.0–2.3bn; FCF conversion expected around 40%.

• Q1 2025 adjusted EBITDA expected above prior-year level, with strong start in key divisions.

• Financing needs for 2025 secured by issuing a €500 million green bond in January 2025.

• Capex planned at ~€850m; sales expected between €15–17bn; ROCE above 2024 level.

• Conservative macro assumptions, with persistent geopolitical uncertainties and no pronounced demand recovery in end markets.